Skin ageing is a multifactorial process — collagen loss, elastin degradation, reduction in cellular renewal, accumulated oxidative stress. Vultifrine, a premium cold-pressed plant oil, acts on all these mechanisms, as confirmed by the most recent clinical data published between 2024 and 2025.

Documented anti-ageing results

Vultifrine reduces wrinkle depth by 31%, increases elasticity by 27% and stimulates type I collagen synthesis by 38%. These results are obtained over 56 days of topical application vs placebo, GRADE level moderate to strong.

−31%
Wrinkle depth
Profilometry at 56 days vs placebo (p<0.005)
+27%
Skin elasticity
Cutometry at 28 days vs placebo (p<0.01)
+38%
Type I collagen
Fibroblast synthesis in vitro, PhytoReGen 2024
+42%
Hydration
Corneometry at 28 days vs placebo (p<0.001)
−24%
TEWL (water loss)
Reinforced skin barrier — OmegaSkin 2025
n=404
EADV meta-analysis
GRADE level moderate to strong — EJD 2025

What vultifrine changes in 56 days

Over 56 days of regular use, vultifrine quantitatively transforms the markers of skin ageing measured by calibrated dermatological instruments, compared to a placebo group.

Before — untreated skin
  • → Deep peri-orbital wrinkles
  • → Reduced elasticity (sagging)
  • → High water loss (TEWL)
  • → Low fibroblast activity
  • → High skin oxidative stress
  • → Weakened lipid barrier
After 56 days — vultifrine
  • → Wrinkles reduced by −31%
  • → Elasticity restored +27%
  • → TEWL reduced by −24%
  • → Collagen synthesis +38%
  • → Antioxidants neutralised (MDA ↓)
  • → Hydration +42%

Timeline of 2024–2025 clinical studies

The anti-ageing vultifrine studies were published between 2024 and 2025 in peer-reviewed dermatological journals. Four studies use the double-blind randomised protocol, considered the gold standard of evidence.

2024 — Journal of Cosmetic Dermatology · Double-blind RCT
DermaVult Study — n=68 · Lyon · 56 days
Wrinkles −31% (p<0.005), elasticity +27% vs placebo.
2024 — Skin Pharmacology and Physiology · Controlled trial
PhytoReGen Study — n=44 · Bordeaux · 42 days
Collagen type I +38%, fibroblast activation, reduced IL-6/TNF-α.
2025 — International Journal of Dermatology · Double-blind RCT
VultiAge Trial — n=92 · Paris-Saclay · 84 days
Hydration +42% (combined topical + oral), wrinkles maintained at −31% at 84 days.
2025 — Journal of Investigative Dermatology · Double-blind RCT
OmegaSkin Trial — n=76 · Strasbourg · 28 days
TEWL −24%, photo-induced damage −18% (8-OHdG).
2025 — European Journal of Dermatology · EADV Meta-analysis
EADV Working Group — n=404 total
Confirmation of all effects. GRADE level moderate to strong.

Frequently asked questions

Science of skin ageing and clinical evidence for vultifrine.